| scholarly article | Q13442814 |
| P50 | author | Olaf Stüve | Q30353210 |
| P2093 | author name string | Bernhard Hemmer | |
| Scott S Zamvil | |||
| B K Kleinschmidt-DeMasters | |||
| Elliot M Frohman | |||
| Nitin J Karandikar | |||
| Michael K Racke | |||
| Todd N Eagar | |||
| Martin S Weber | |||
| Maria del Pilar Martin | |||
| Petra D Cravens | |||
| Ryan Winger | |||
| P433 | issue | 12 | |
| P921 | main subject | dendritic cell | Q506253 |
| P304 | page(s) | 1596-1603 | |
| P577 | publication date | 2008-10-13 | |
| P1433 | published in | Archives of Neurology | Q15766672 |
| P1476 | title | Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab | |
| P478 | volume | 65 |
| Q51052730 | 2-Chlorodeoxyadenosine (cladribine) induces apoptosis in human monocyte-derived dendritic cells. |
| Q38268951 | A risk classification for immunosuppressive treatment-associated progressive multifocal leukoencephalopathy |
| Q54207057 | Aging and lymphocyte changes by immunomodulatory therapies impact PML risk in multiple sclerosis patients. |
| Q30576988 | Alpha4beta1 integrin mediates the recruitment of immature dendritic cells across the blood-brain barrier during experimental autoimmune encephalomyelitis |
| Q37546119 | An update on the efficacy of non-steroidal anti-inflammatory drugs in Alzheimer's disease |
| Q35957449 | Antibody to α4 integrin suppresses natural killer cells infiltration in central nervous system in experimental autoimmune encephalomyelitis |
| Q41537684 | Are inflammatory profiles the key to personalized Alzheimer's treatment? |
| Q35619220 | CD4 cell response to interval therapy with natalizumab |
| Q91986386 | CD49d/CD29-integrin controls the accumulation of plasmacytoid dendritic cells into the CNS during neuroinflammation |
| Q90638165 | CD8 T-cell Recruitment Into the Central Nervous System of Cuprizone-Fed Mice: Relevance to Modeling the Etiology of Multiple Sclerosis |
| Q36416627 | Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis |
| Q38850493 | Current pharmacotherapy and putative disease-modifying therapy for Alzheimer's disease |
| Q37737296 | Current therapeutic targets for the treatment of Alzheimer's disease |
| Q36553718 | Cutting Edge: CD99 Is a Novel Therapeutic Target for Control of T Cell-Mediated Central Nervous System Autoimmune Disease. |
| Q92533933 | Dendritic Cell Accumulation in the Gut and Central Nervous System Is Differentially Dependent on α4 Integrins |
| Q38771884 | Dendritic cells as therapeutic targets in neuroinflammation |
| Q39020365 | Dendritic cells in central nervous system autoimmunity. |
| Q38078160 | Dendritic cells in multiple sclerosis: key players in the immunopathogenesis, key players for new cellular immunotherapies? |
| Q50086043 | ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an Infectious Diseases perspective (Immune checkpoint inhibitors, cell adhesion inhibitors, sphingosine-1-phosphat |
| Q33975585 | Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: a cross-sectional observational study in patients with multiple sclerosis |
| Q33877744 | Emerging viral infections of the central nervous system: part 2 |
| Q37947688 | Epidemiological findings of vascular risk factors in Alzheimer's disease: implications for therapeutic and preventive intervention |
| Q34135724 | Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions |
| Q26770818 | Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis |
| Q27022494 | Extracellular Vesicles in Multiple Sclerosis: What are They Telling Us? |
| Q28740884 | Functional energetics of CD4+-cellular immunity in monoclonal antibody-associated progressive multifocal leukoencephalopathy in autoimmune disorders |
| Q36374681 | H(1)R expression by CD11B(+) cells is not required for susceptibility to experimental allergic encephalomyelitis |
| Q53639982 | High interindividual variability in the CD4/CD8 T cell ratio and natalizumab concentration levels in the cerebrospinal fluid of patients with multiple sclerosis. |
| Q90171276 | Hippocampal subfield transcriptome analysis in schizophrenia psychosis |
| Q37980042 | Human polyomavirus JC reactivation and pathogenetic mechanisms of progressive multifocal leukoencephalopathy and cancer in the era of monoclonal antibody therapies |
| Q34818048 | Immunological Markers for PML Prediction in MS Patients Treated with Natalizumab |
| Q56337838 | Inflammageing: chronic inflammation in ageing, cardiovascular disease, and frailty |
| Q37069901 | Inflammation and clinical presentation in neurodegenerative disease: a volatile relationship |
| Q36379542 | Inflammatory Eicosanoids Increase Amyloid Precursor Protein Expression via Activation of Multiple Neuronal Receptors |
| Q57599442 | Innate Immunity in the CNS - A Focus on the Myeloid Cell |
| Q36884649 | Innate-adaptive crosstalk: how dendritic cells shape immune responses in the CNS. |
| Q34912684 | Integrin targeted therapeutics |
| Q26851694 | Intrathecal IgG synthesis: a resistant and valuable target for future multiple sclerosis treatments |
| Q39906123 | Knowns and unknowns in the future of multiple sclerosis treatment |
| Q91260333 | Lack of specific T- and B-cell clonal expansions in multiple sclerosis patients with progressive multifocal leukoencephalopathy |
| Q26822941 | Leukocyte integrins: role in leukocyte recruitment and as therapeutic targets in inflammatory disease |
| Q28730755 | Long-term decrease in VLA-4 expression and functional impairment of dendritic cells during natalizumab therapy in patients with multiple sclerosis |
| Q37696989 | Long-term safety and efficacy of natalizumab in relapsing-remitting multiple sclerosis: impact on quality of life. |
| Q28731914 | Lymphocyte subsets show different response patterns to in vivo bound natalizumab--a flow cytometric study on patients with multiple sclerosis |
| Q37857752 | Managing MS in a changing treatment landscape. |
| Q39219113 | Migration of encephalitogenic CD8 T cells into the central nervous system is dependent on the α4β1-integrin |
| Q37970962 | Modulation of inflammatory pathways by the immune cholinergic system. |
| Q28270413 | Monoclonal antibodies and progressive multifocal leukoencephalopathy |
| Q37968620 | Monoclonal antibodies and recombinant immunoglobulins for the treatment of multiple sclerosis. |
| Q37814815 | Monoclonal antibody therapy in multiple sclerosis: Paradigm shifts and emerging challenges |
| Q37568787 | Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project |
| Q37778944 | Natalizumab and progressive multifocal leukoencephalopathy: what are the causal factors and can it be avoided? |
| Q42181572 | Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF. |
| Q34409340 | Natalizumab in the treatment of multiple sclerosis |
| Q50979570 | Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. |
| Q30659100 | Natalizumab: a review of its use in the management of relapsing-remitting multiple sclerosis |
| Q35150206 | Peripherally triggered and GSK-3β-driven brain inflammation differentially skew adult hippocampal neurogenesis, behavioral pattern separation and microglial activation in response to ibuprofen. |
| Q92722359 | Perspectives on Current and Novel Treatments for Inflammatory Bowel Disease |
| Q28546343 | Plasma membrane profiling defines an expanded class of cell surface proteins selectively targeted for degradation by HCMV US2 in cooperation with UL141 |
| Q34230150 | Pre-existing T- and B-cell defects in one progressive multifocal leukoencephalopathy patient |
| Q37798242 | Progressive multifocal leukoencephalopathy and newer biological agents |
| Q45182536 | Progressive multifocal leukoencephalopathy: Can we reduce risk in patients receiving biological immunomodulatory therapies? |
| Q37755922 | Progressive multifocal leukoencephalopathy: what's new? |
| Q37492253 | Regulation of innate immune responses in the brain |
| Q26999705 | Review article: anti-adhesion therapies for inflammatory bowel disease |
| Q33832088 | Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis |
| Q28082878 | Role of the immunogenic and tolerogenic subsets of dendritic cells in multiple sclerosis |
| Q34542922 | Safety of monoclonal antibodies for the treatment of multiple sclerosis. |
| Q38020964 | T-cell trafficking in the central nervous system |
| Q90625149 | TLR3 agonism re-establishes CNS immune competence during α4-integrin deficiency |
| Q37083046 | Tanshinone IIA attenuates experimental autoimmune encephalomyelitis in rats |
| Q38098493 | Targeting cells in motion: migrating toward improved therapies |
| Q37780678 | Targeting dendritic cells to treat multiple sclerosis. |
| Q34243433 | Targeting leukocyte migration and adhesion in Crohn's disease and ulcerative colitis |
| Q35669064 | Th17 lymphocytes traffic to the central nervous system independently of α4 integrin expression during EAE |
| Q33873941 | The Cache County Study on Memory in Aging: factors affecting risk of Alzheimer's disease and its progression after onset |
| Q37857982 | The immunopathophysiology of multiple sclerosis |
| Q37965603 | The link between VLA-4 and JC virus reactivation |
| Q51165195 | The promise of anti-inflammatory therapies for CNS injuries and diseases. |
| Q47859915 | To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. |
| Q37772026 | Translational research in neurology and neuroscience 2010: multiple sclerosis |
| Q37957123 | Treating multiple sclerosis with natalizumab |
| Q26823444 | Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps |
| Q38044681 | Update on progressive multifocal leukoencephalopathy |
| Q34038890 | Using genetics to enable studies on the prevention of Alzheimer's disease |
| Q27021612 | Vedolizumab for inflammatory bowel disease: Changing the game, or more of the same? |
| Q64102803 | Vedolizumab in Japanese patients with ulcerative colitis: A Phase 3, randomized, double-blind, placebo-controlled study |
| Q37921761 | What happens when natalizumab therapy is stopped? |
| Q83630544 | [Progressive multifocal leukoencephalopathy. Undesirable side effect of immunotherapy] |
Search more.